BR100 Increased By (0.53%)
BR30 Increased By (0.44%)
KSE100 Increased By (0.72%)
KSE30 Increased By (0.57%)
AGHA 6.04 Increased By ▲ 0.02 (0.33%)
BECO 3.89 Increased By ▲ 0.08 (2.1%)
BML 61.78 Increased By ▲ 5.34 (9.46%)
BOP 28.19 Increased By ▲ 0.09 (0.32%)
CNERGY 11.95 Decreased By ▼ -0.33 (-2.69%)
CSIL 5.37 Increased By ▲ 0.08 (1.51%)
FCCL 54.25 Increased By ▲ 0.44 (0.82%)
FFL 12.95 Increased By ▲ 0.15 (1.17%)
FNEL 1.14 Increased By ▲ 0.02 (1.79%)
KEL 5.65 Increased By ▲ 0.01 (0.18%)
KOSM 5.34 Decreased By ▼ -0.04 (-0.74%)
LOTCHEM 23.77 Increased By ▲ 0.22 (0.93%)
MLCF 93.10 Increased By ▲ 1.14 (1.24%)
NBP 163.99 Increased By ▲ 1.75 (1.08%)
NCPL 48.80 Decreased By ▼ -0.11 (-0.22%)
NPL 50.40 Decreased By ▼ -0.11 (-0.22%)
OGDC 303.40 Increased By ▲ 1.72 (0.57%)
PACE 9.13 No Change ▼ 0.00 (0%)
PAEL 31.99 Increased By ▲ 0.18 (0.57%)
PIBTL 12.79 Increased By ▲ 0.01 (0.08%)
PPL 211.90 Decreased By ▼ -0.16 (-0.08%)
PRL 84.49 Decreased By ▼ -2.77 (-3.17%)
PTC 44.72 Increased By ▲ 0.76 (1.73%)
SSGC 22.79 Decreased By ▼ -0.07 (-0.31%)
TBL 8.96 Increased By ▲ 0.05 (0.56%)
TELE 6.50 Increased By ▲ 0.06 (0.93%)
TPL 24.12 Increased By ▲ 0.03 (0.12%)
TPLP 12.24 Increased By ▲ 0.08 (0.66%)
TREET 23.33 Decreased By ▼ -0.17 (-0.72%)
TRG 51.85 Decreased By ▼ -0.02 (-0.04%)
World

Rovi to make active agents for Moderna COVID-19 vaccine

  • Rovi will start manufacturing of the active agents at its plant in Granada, having previously only packaged vaccines that had been produced in Switzerland, it said in a statement.
Published Updated
By

MADRID: Spanish pharmaceuticals company Rovi plans to start making the active agents for up to 100 million doses of the COVID-19 vaccine developed by Moderna , it said on Monday without disclosing the size of the investment.

Rovi will start manufacturing of the active agents at its plant in Granada, having previously only packaged vaccines that had been produced in Switzerland, it said in a statement.

Madrid-based Rovi, which already has an agreement with Moderna to fill vials and package its vaccines, expects to start supplying markets other than the United States in the third quarter of 2021, the statement said.

Comments

Comments are closed for this article.